MX2020006005A - Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca. - Google Patents

Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.

Info

Publication number
MX2020006005A
MX2020006005A MX2020006005A MX2020006005A MX2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A MX 2020006005 A MX2020006005 A MX 2020006005A
Authority
MX
Mexico
Prior art keywords
heart failure
block copolymers
methods
micelles
treat
Prior art date
Application number
MX2020006005A
Other languages
English (en)
Inventor
Afsaneh Lavasanifar
Anthony Ernest Bolton
Original Assignee
Cardiol Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiol Therapeutics Inc filed Critical Cardiol Therapeutics Inc
Publication of MX2020006005A publication Critical patent/MX2020006005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Copolímeros bloque anfifílicos formadores de micelas que se usan para dirigirse a células cardíacas (por ejemplo, células fibróticas) de un sujeto que padece insuficiencia cardíaca, micelas que contienen los copolímeros bloque anfifílicos formadores de micelas junto con un agente cardioactivo y composiciones y métodos relacionados para tratar o prevenir la insuficiencia cardíaca, por ejemplo insuficiencia cardíaca con fracción de eyección preservada (HFpEF) también conocida como insuficiencia cardíaca diastólica.
MX2020006005A 2017-12-12 2018-12-10 Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca. MX2020006005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597740P 2017-12-12 2017-12-12
PCT/CA2018/051573 WO2019113685A1 (en) 2017-12-12 2018-12-10 Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure

Publications (1)

Publication Number Publication Date
MX2020006005A true MX2020006005A (es) 2020-08-17

Family

ID=66818773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006005A MX2020006005A (es) 2017-12-12 2018-12-10 Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.

Country Status (7)

Country Link
US (1) US20210085801A1 (es)
EP (1) EP3723731A4 (es)
AU (1) AU2018384096B2 (es)
BR (1) BR112020006191A2 (es)
CA (1) CA3076248C (es)
MX (1) MX2020006005A (es)
WO (1) WO2019113685A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3157812C (en) * 2019-10-25 2024-10-22 Cardiol Therapeutics Inc. Cannabidiol compositions for use in treating heart conditions
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
JP2023516284A (ja) * 2020-02-19 2023-04-19 マーチャント，シュリーマ カンナビジオールの組成物および治療的使用
TW202210072A (zh) * 2020-05-26 2022-03-16 美商羅德科技公司 用於鼻內或吸入遞送之大麻素組合物及劑型
CN114262442B (zh) * 2021-12-24 2023-05-02 厦门金达威生物科技有限公司 一种两亲聚合物和脂溶性营养素纳米颗粒及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
AU2003249317B2 (en) * 2002-07-19 2007-08-02 Institute Of Materials Research And Engineering Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
CA2580305A1 (en) * 2004-06-02 2005-12-15 The Governors Of The University Of Alberta Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs
JP5933889B2 (ja) * 2006-03-21 2016-06-15 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ 新規なポリ（エチレンオキサイド）−ブロックーポリ（エステル）ブロック共重合体
EP2382966A1 (en) * 2010-03-12 2011-11-02 DSM IP Assets B.V. Micelle compositions and process for the preparation thereof
MX376077B (es) * 2013-03-13 2025-03-07 Univ Cincinnati Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.

Also Published As

Publication number Publication date
US20210085801A1 (en) 2021-03-25
CA3076248A1 (en) 2019-06-20
CA3076248C (en) 2025-05-13
BR112020006191A2 (pt) 2020-10-06
EP3723731A1 (en) 2020-10-21
AU2018384096B2 (en) 2021-04-15
AU2018384096A1 (en) 2020-03-26
WO2019113685A1 (en) 2019-06-20
EP3723731A4 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
MX2020006005A (es) Copolimeros bloque anfifilicos, micelas y metodos para tratar o prevenir insuficiencia cardiaca.
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
CO2021005231A2 (es) Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha)
EP4219724A3 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP4339287A3 (en) Modified cells and methods of therapy
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
WO2016182959A8 (en) Optimized crispr/cas9 systems and methods for gene editing in stem cells
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
PH12017502107A1 (en) Triazole agonists of the apj receptor
WO2017163132A3 (en) Use of umbilical cord blood derived exosomes for tissue repair
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
MX387788B (es) Uso de agentes activos durante tratamientos quimicos.
MD4685B1 (ro) Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
WO2015191781A3 (en) Apelin polypeptides
HK1208361A1 (en) Multi-target modulation for treating fibrosis and inflammatory conditions
WO2017178883A3 (en) Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
EA202092748A1 (ru) Модуляторы экспрессии apol1
WO2018048899A8 (en) Use of resected liver serum for whole liver engineering
CL2021003045A1 (es) Tratamiento de la disfunción sistólica